&w=3840&q=100)
Here's why Marksans Pharma share price increased over 2% in trade on May 15
Marksans Pharma share price: Pharmaceutical company Marksans Pharma shares rose up to 2.18 per cent to hit an intraday high of ₹243.40 per share on Thursday, May 15, 2025.
However, at 11:20 PM, Marksans Pharma shares pared gains and were trading merely 0.08 per cent higher at ₹238 per share. In comparison, BSE Sensex was trading 0.10 per cent lower at 81,247.08 level.
Why led to the up move in Marksans Pharma share price?
The northward move in Marksans Pharma came after the company's wholly-owned subsidiary, Relonchem, received marketing authorisation for the product Gabapentin 50 mg/ml oral solution from UK Medicines & Healthcare Products Regulatory Agency (UK MHRA).
In an exchange filing, Marksans Pharma said, 'Marksans Pharma hereby announces that its wholly owned subsidiary Relonchem Limited has received marketing authorisation for the product Gabapentin 50 mg/ml oral solution from UK Medicines & Healthcare Products Regulatory Agency.'
Gabapentin is commonly used to treat epilepsy and nerve pain. In epilepsy, it's believed to work by calming abnormal electrical activity in the brain that leads to seizures. It's also effective for managing nerve pain, which may result from conditions such as diabetes, shingles, or physical injuries.
Marksans Pharma results
Marksans Pharma will release its March quarter of financial year 2025 (Q4FY25) results on May 19. The board will also consider recommending a dividend on the equity shares for FY25.
In Q3FY25, Marksans Pharma's operating revenue stood at ₹681.8 crore, up 16.3 per cent year-on-year (Y-o-Y), driven growth across key markets, led by US region
The gross profit stood at ₹383.5 crore, up 22.4 per cent Y-o-Y, with a gross margin expansion of 279 basis points (bps) Y-o-Y to 56.2 per cent. The growth was attributed to softening of raw material prices and a better product mix, the company said in a statement.
About Marksans Pharma
Marksans Pharma, based in Mumbai, specialises in the research, manufacturing, and marketing of generic pharmaceutical formulations in global markets. The company operates manufacturing facilities in India, the USA, and the UK, all of which are approved by regulatory agencies, including the USFDA, UKMHRA, and Australian TGA.
Marksans Pharma offers a diverse product portfolio across key therapeutic areas, such as cardiovascular (CVS), central nervous system (CNS), anti-diabetic, pain management, gastroenterology, and anti-allergies. These products are marketed worldwide.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
New Indian Express
2 hours ago
- New Indian Express
Realty shares zoom ahead of RBI monetary policy decision
Real estate stocks jumped as much as 10% on Thursday in anticipation of the RBI's Monetary Policy Committee (MPC) decision, scheduled for Friday. Market expectations are tilted toward a 25-basis-point repo rate cut, along with a continued accommodative stance—a positive signal for rate-sensitive sectors like real estate. The Nifty Realty index was the top-performing sectoral index on Thursday, climbing up to 2% in intraday trade before settling 1.75% higher. Since May 9, the realty index has surged more than 20%, outpacing the 3% gain made by the benchmark Nifty50 index. Meanwhile, India's equity market extended gains on Thursday as the BSE Sensex surged 443.79 points or 0.55% to close at 81,442.04, and the NSE Nifty50 advanced 130.70 points or 0.53% to settle at 24,750.90. Investors demonstrated robust demand for real estate stocks in anticipation of the RBI's upcoming policy decision on Friday. Market experts widely expect a 25-basis-point reduction in the repo rate -marking the third consecutive cut - as inflationary pressures ease. A small fraction also hopes the RBI goes for a 50 bps rate cut after retail inflation dropped to 3.16% in April, giving the central bank wider flexibility to prioritize economic expansion.
New Indian Express
3 hours ago
- New Indian Express
Equity benchmarks end higher on rate cut hopes, pharma and realty rally
CHENNAI: Indian equity markets ended on a strong note on Thursday, June 5, as expectations of a potential interest rate cut by the Reserve Bank of India (RBI) lifted investor sentiment. Gains in pharmaceutical and realty stocks, coupled with supportive global cues—such as declining US Treasury yields and a weaker dollar—further buoyed market confidence. After a cautious start, benchmark indices saw sharp gains in the second half of the session. The BSE Sensex closed at 81,442.19, up 443.79 points or 0.55%, after touching an intraday high of 81,911. The NSE Nifty50 advanced 130.7 points, or 0.53%, to settle at 24,750.90. Broader Markets and Sectoral Performance Broader indices outperformed the benchmarks today with Nifty Midcap100 gaining 0.65%, and Nifty Smallcap100 rising 0.96%. Sectorally, Nifty Realty led the rally with a jump of 1.75%, followed by Pharma (+1.28%) and Healthcare (+1.07%). Other sectors including Metal, IT, Energy, Financial Services, and Oil & Gas also ended in the green. However, Nifty PSU Bank fell 0.58%, along with losses in Media and Auto sectors, indicating selective pressure in rate-sensitive and cyclical pockets.
Business Standard
4 hours ago
- Business Standard
INR tracks positive cues from local equities; Sensex jumps over 400 points, Nifty settles at 24,750
The Indian rupee snapped its two-day losing streak and closed 7 paise higher at 85.80 (provisional) against the US dollar on Thursday, supported by positive domestic equities and a rise in regional currencies. Domestic shares ended modestly higher with the benchmark S&P/BSE Sensex gaining 443.79 points, or 0.55 percent, to 81,442.04. The broader NSE Nifty index closed up 130.70 points, or 0.53 percent, at 24,750.90 while the BSE mid-cap and small-cap indexes gained 0.4 percent and 0.7 percent, respectively. However, rising international oil prices and dollar index steadying near 99 mark limited much gains in the counter. Meanwhile, market participants are now keenly awaiting the outcome of the Reserve Bank of India's (RBI's) monetary policy meeting for further cues. On the NSE, USDINR pair traded at 85.89, down 0.10% on the day. Overseas dollar under pressure ahead of Fridays jobs data and positive local equities supporting the Indian unit weighed on the counter.
